# Dupilumab Effects Against Aeroallergen Challenge

> **NCT05720325** · PHASE2 · RECRUITING · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 88 (estimated)

## Conditions studied

- Asthma, Allergic

## Interventions

- **DRUG:** Dupilumab
- **OTHER:** House Dust Mites (HDM)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05720325
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-29
- **Primary completion:** 2026-11
- **Final completion:** 2027-11
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05720325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05720325, "Dupilumab Effects Against Aeroallergen Challenge". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT05720325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*